The World Health Organisation (WHO) reports that 57 countries, one of which is New Zealand, collect 100% of their blood supply from voluntary, unpaid donors. Regular volunteers are considered the safest as the incidence of blood borne infections amongst these donors is minute. In support of World Blood Donor Day on June 14th, staff from […]
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has opened a new R&D facility within its Kawasaki Innovation Gateway at SKYFRONT in the city of Kawasaki, Kanagawa Prefecture, to pursue R&D in bioinformatics, a key technology toward the realisation of personalised medicine.
In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we will be extending our provision of donations for a five-year period from 2018. By participating in the GHIT Fund, we will move forward with initiatives to develop and provide new reagents for infectious diseases in the aim of eradicating infectious diseases in developing countries.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement with Oxford Gene Technology IP Limited (HQ: Oxfordshire county, United Kingdom; CEO: Michael Evans; “OGT”) to acquire all shares in OGT (the “Acquisition”). Through this move, Sysmex aims to obtain OGT’s business and expertise in the cytogenetics1 domain and its reagent development capabilities used in next-generation sequencers (NGSs)2, thereby reinforcing its base in the life science business.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has received the Invention Award in the National Commendation for Invention1, sponsored by the Japan Institute of Invention and Innovation, for its hematology analyzers that enables the rapid evaluation of the effects of administering iron preparations. The award ceremony is scheduled to be held in Tokyo on Monday, June 12.
Sysmex New Zealand has been synonymous with the Delphic and Eclair suite of lab and clinical IT solutions for over three decades. The Sysmex New Zealand team are excited to announce, effective 1st May we will be managing the direct sales and support of the Sysmex Urinalysis instrument portfolio, under the guidance and expertise of […]
Sysmex New Zealand has appointed a new senior management team. James Webster has stepped aside as Sysmex New Zealand CEO to focus his full attention on his role as Sysmex Australia CEO. Assuming the position of Sysmex New Zealand CEO is Arjit Bhana, formerly the company’s General Manager. James Webster said “I may have moved […]
Sysmex New Zealand has signed a new sponsorship agreement with Kidney Kids NZ, a not-for-profit organisation, founded in 1990, that provides support and advocacy services to families of children with kidney disorders across New Zealand. Kidney Kids’ vision is for children with kidney disorders and their families to lead the best lives possible. Rachel Barrett, […]
The following article was written by Kate McDonald and published in Pulse+IT on 5 April 2017. CareConnect consolidates on one site as GPs get single sign-on to TestSafe General practitioners in NZ’s Northern region now have single sign-on access to the TestSafe clinical data repository through the My Practice and Medtech32 practice management systems, allowing […]
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces the establishment of a new company, Sysmex Harmony Co., Ltd., to promote the employment of people with disabilities.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and National University Corporation Kobe University (Location: Kobe, Japan; President: Hiroshi Takeda) announce the establishment of two funded courses to encourage leading-edge cancer research at the Kobe University Graduate School of Medicine, as Department of International Clinical Cancer Research.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and the University of Tokyo (Location: Bunkyo-ku, Tokyo; President: Makoto Gonokami) have entered into a research collaboration agreement involving the development of a target gene panel1. The objective is to analyze lung cancer, sarcoma and other specified types of diseases, and analyze genetic mutations related to rare diseases2 with a view to the clinical application of genomic medicine.